In Friday’s Wall Street session, Kazia Therapeutics Limited (NASDAQ:KZIA) shares traded at $0.69, up 1.47% from the previous session.
4 analysts cover Kazia Therapeutics Limited (NASDAQ:KZIA), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $12.68 and a low of $3.17, we find $7.92. Given the previous closing price of $0.68, this indicates a potential upside of 1064.71 percent. KZIA stock price is now -36.86% away from the 50-day moving average and -84.01% away from the 200-day moving average. The market capitalization of the company currently stands at $10.50M.
The stock has received a hold rating from 2 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $7.92 as their price target over the next twelve months.
With the price target of $18, Maxim Group recently initiated with Buy rating for Kazia Therapeutics Limited (NASDAQ: KZIA). On January 05, 2021, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $17.
A total of 28.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KZIA stock. A new stake in Kazia Therapeutics Limited shares was purchased by TWO SIGMA SECURITIES, LLC during the first quarter worth $17,000. CITADEL ADVISORS LLC invested $16,000 in shares of KZIA during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Kazia Therapeutics Limited valued at approximately $8,000. In total, there are 14 active investors with 2.10% ownership of the company’s stock.
On Friday morning Kazia Therapeutics Limited (NASDAQ: KZIA) stock kicked off with the opening price of $0.6768. During the past 12 months, Kazia Therapeutics Limited has had a low of $0.65 and a high of $11.79. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.60, and a quick ratio of 1.60. The fifty day moving average price for KZIA is $1.0788 and a two-hundred day moving average price translates $4.2865 for the stock.
The latest earnings results from Kazia Therapeutics Limited (NASDAQ: KZIA) was released for Jun, 2022.
Moreover, the firm recently paid out its quarterly dividend on 01/25/2013. Investors who held shares on 11/19/2012 were paid a $4.0928 dividend.
Kazia Therapeutics Limited(KZIA) Company Profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.